What will happen with 23andMe’s personal genetic data now that it’s been bought in a bankruptcy auction

[R]egeneron Pharmaceuticals has agreed to buy the genetic testing firm 23andMe Holding for $256m through a bankruptcy auction, the companies announced [last week].

Regeneron said it will comply with 23andMe’s privacy policies and applicable laws with respect to the use of customer data and that it is ready to detail its intended use of the data to a court-appointed overseer. The companies expect to close the deal in the third quarter.

The US does not currently have comprehensive privacy regulation that would establish enforceable guardrails around how Regeneron will store, use and share the genetic data it is acquiring from 23andMe.

Related on the SLP

With 23andMe’s bankruptcy, questions emerge about the the private genetic data of its 6.9 million customers 23andMe moves to mend fences with FDA, seeks Bloom syndrome test approval

Viewpoint: RFK Jr. touts AI to guide health care…but searches using the technology he champions expose him as scientifically illiterate

Viewpoint: ‘Bureaucratic and economic obstacles’ to agricultural biotechnology: Europe creeps into the 21st century, but blocks remain

Viewpoint: How the anti-abortion movement twists medical facts and promotes science misinformation